BACKGROUND: Recent studies suggest a rising rate of cardiovascular disease (CVD) in HIV-infected subjects. Although most countries have an aging HIV-infected population, there remains a lack of knowledge about associated cardiovascular diseases. METHODS: This ongoing prospective multicentre observational cohort study aims to elucidate CVD prevalence in HIV-infected outpatients by standardized non-invasive cardiovascular screening. Cardiovascular and coronary risk was calculated using Framingham risk scores. RESULTS: 803 HIV-infected subjects (mean age 44.2 years, female 16.6 %) were included. The prevalence of CVD in HIV-infected subjects was 10.1 % (95 % CI 8.0-12.2 %). Aging HIV-infected patients (≥45 years, N = 348) exhibited significantly increased rates of CVD, including an elevated frequency of coronary artery disease (7.5 vs. 1.8 %, p < 0.001), myocardial infarction (6.0 vs. 1.8 %, p = 0.002) and peripheral arterial diseases (4.6 vs. 1.5 %, p < 0.017). Furthermore, aging patients exhibited a higher rate of chronic heart failure (5.2 vs. 1.5 %, p < 0.001), predominantly of ischemic etiology. In multivariate analyses, age (OR 2.05 per decade, 95 % CI 1.64-2.56), smoking (OR 5.96 per decade, 95 % CI 2.31-15.38) and advanced symptomatic HIV infection (OR 2.60 per decade, 95 % CI 1.31-5.15), were significantly associated with the prevalence of CVD. Based on the 10-year cardiovascular risk estimation, a disproportionate increase in cardiac events has to be expected in aging HIV-infected subjects in the next decades (≥45 years/<45 years 16.4 vs. 4.2 %, p < 0.001). CONCLUSION: CVD in aging HIV-infected population is an increasing medical challenge. In the era of antiretroviral therapy, prevention and diagnostic strategies are essential to reduce the prevalence of CVD in HIV-infected patients.
BACKGROUND: Recent studies suggest a rising rate of cardiovascular disease (CVD) in HIV-infected subjects. Although most countries have an aging HIV-infected population, there remains a lack of knowledge about associated cardiovascular diseases. METHODS: This ongoing prospective multicentre observational cohort study aims to elucidate CVD prevalence in HIV-infected outpatients by standardized non-invasive cardiovascular screening. Cardiovascular and coronary risk was calculated using Framingham risk scores. RESULTS: 803 HIV-infected subjects (mean age 44.2 years, female 16.6 %) were included. The prevalence of CVD in HIV-infected subjects was 10.1 % (95 % CI 8.0-12.2 %). Aging HIV-infectedpatients (≥45 years, N = 348) exhibited significantly increased rates of CVD, including an elevated frequency of coronary artery disease (7.5 vs. 1.8 %, p < 0.001), myocardial infarction (6.0 vs. 1.8 %, p = 0.002) and peripheral arterial diseases (4.6 vs. 1.5 %, p < 0.017). Furthermore, aging patients exhibited a higher rate of chronic heart failure (5.2 vs. 1.5 %, p < 0.001), predominantly of ischemic etiology. In multivariate analyses, age (OR 2.05 per decade, 95 % CI 1.64-2.56), smoking (OR 5.96 per decade, 95 % CI 2.31-15.38) and advanced symptomatic HIV infection (OR 2.60 per decade, 95 % CI 1.31-5.15), were significantly associated with the prevalence of CVD. Based on the 10-year cardiovascular risk estimation, a disproportionate increase in cardiac events has to be expected in aging HIV-infected subjects in the next decades (≥45 years/<45 years 16.4 vs. 4.2 %, p < 0.001). CONCLUSION: CVD in aging HIV-infected population is an increasing medical challenge. In the era of antiretroviral therapy, prevention and diagnostic strategies are essential to reduce the prevalence of CVD in HIV-infectedpatients.
Authors: Denise Fischer; Ingrid Kindermann; Julia Karbach; Philipp Y Herzberg; Christian Ukena; Christine Barth; Matthias Lenski; Felix Mahfoud; Franziska Einsle; Stephanie Dannemann; Michael Böhm; Volker Köllner Journal: Clin Res Cardiol Date: 2011-10-21 Impact factor: 5.460
Authors: U H Iloeje; Y Yuan; G L'italien; J Mauskopf; S D Holmberg; A C Moorman; K C Wood; R D Moore Journal: HIV Med Date: 2005-01 Impact factor: 3.180
Authors: Raimund Erbel; Stefan Möhlenkamp; Susanne Moebus; Axel Schmermund; Nils Lehmann; Andreas Stang; Nico Dragano; Dietrich Grönemeyer; Rainer Seibel; Hagen Kälsch; Martina Bröcker-Preuss; Klaus Mann; Johannes Siegrist; Karl-Heinz Jöckel Journal: J Am Coll Cardiol Date: 2010-10-19 Impact factor: 24.094
Authors: Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel Journal: Circulation Date: 2008-01-22 Impact factor: 29.690
Authors: Nina Friis-Møller; Peter Reiss; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa El-Sadr; Rodolphe Thiébaut; Stephane De Wit; Ole Kirk; Eric Fontas; Matthew G Law; Andrew Phillips; Jens D Lundgren Journal: N Engl J Med Date: 2007-04-26 Impact factor: 91.245
Authors: Jason D Barbour; Emilie C Jalbert; Dominic C Chow; Louie Mar A Gangcuangco; Philip J Norris; Sheila M Keating; John Heitman; Lorna Nagamine; Todd Seto; Lishomwa C Ndhlovu; Beau K Nakamoto; Howard N Hodis; Nisha I Parikh; Cecilia M Shikuma Journal: Atherosclerosis Date: 2013-10-31 Impact factor: 5.162
Authors: Lutz Frankenstein; Henrik Hees; Tobias Taeger; Hanna Froehlich; Andreas Dösch; Rita Cebola; Christian Zugck; Hugo A Katus Journal: Clin Res Cardiol Date: 2013-06-26 Impact factor: 5.460
Authors: Anne-Lise Paisible; Chung-Chou H Chang; Kaku A So-Armah; Adeel A Butt; David A Leaf; Matthew Budoff; David Rimland; Roger Bedimo; Matthew B Goetz; Maria C Rodriguez-Barradas; Heidi M Crane; Cynthia L Gibert; Sheldon T Brown; Hilary A Tindle; Alberta L Warner; Charles Alcorn; Melissa Skanderson; Amy C Justice; Matthew S Freiberg Journal: J Acquir Immune Defic Syndr Date: 2015-02-01 Impact factor: 3.731
Authors: Jacek Budzyński; Marek Koziński; Maria Kłopocka; Julia Maria Kubica; Jacek Kubica Journal: Clin Res Cardiol Date: 2014-05-10 Impact factor: 5.460
Authors: Danielle C Ompad; Molly Kingdon; Sandra Kupprat; Sophia N Halkitis; Erik David Storholm; Perry N Halkitis Journal: Behav Med Date: 2014 Impact factor: 3.104